Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328073 | 0.90 | PLA2G4A (0.38) | PLA2G4AS1PR1S1PR4CYP2C9S1PR5 | |
| SCHEMBL4341174 | 0.90 | PPARG (0.38) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 | |
| SCHEMBL13819541 | 0.87 | PLA2G4A (0.36) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 | |
| SCHEMBL4335047 | 0.87 | PLA2G4A (0.38) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 | |
| SCHEMBL4329911 | 0.87 | PLA2G4A (0.44) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 | |
| SCHEMBL4342749 | 0.84 | PLA2G4A (0.42) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 | |
| SCHEMBL4343659 | 0.84 | PLA2G4A (0.41) | PLA2G4A | |
| SCHEMBL4337058 | 0.84 | PLA2G4A (0.41) | PLA2G4ACYP2C9MTNR1AMTNR1BMCL1 | |
| SCHEMBL4335943 | 0.82 | FFAR1 (0.35) | PLA2G4AALKMTNR1AMTNR1BNQO2 | |
| SCHEMBL4331747 | 0.82 | PPARG (0.42) | PLA2G4AMTNR1AMTNR1BMCL1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MRGPRX4 428/4885PLA2G4A 3556/4885S1PR1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.